Dian Su

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9370481/publications.pdf

Version: 2024-02-01

758635 940134 16 444 12 16 citations h-index g-index papers 570 16 16 16 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Future of Biotransformation Science in the Pharmaceutical Industry. Drug Metabolism and Disposition, 2022, 50, 258-267.	1.7	8
2	An Integrated Strategy for Assessing the Metabolic Stability and Biotransformation of Macrocyclic Peptides in Drug Discovery toward Oral Delivery. Analytical Chemistry, 2022, 94, 2032-2041.	3.2	6
3	Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency. Frontiers in Pharmacology, 2021, 12, 687926.	1.6	40
4	Improved translation of stability for conjugated antibodies using an in vitro whole blood assay. MAbs, 2020, 12, 1715705.	2.6	9
5	Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues. Drug Metabolism and Disposition, 2019, 47, 1146-1155.	1.7	20
6	A Novel Depurination Methodology to Assess DNA Alkylation of Chloro-Bis-Seco-Cyclopropylbenzoindoles Allowed for Comparison of Minor-Groove Reactivity. Drug Metabolism and Disposition, 2019, 47, 547-555.	1.7	4
7	Antibody–Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. Bioconjugate Chemistry, 2019, 30, 1356-1370.	1.8	15
8	Modulating Antibody–Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification. Bioconjugate Chemistry, 2018, 29, 1155-1167.	1.8	50
9	Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates. Molecular Cancer Therapeutics, 2018, 17, 677-685.	1.9	30
10	Immolation of <i>p</i> -Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibody–Drug Conjugates with Phenol-Containing Payloads. Bioconjugate Chemistry, 2018, 29, 267-274.	1.8	27
11	LC–MS Challenges in Characterizing and Quantifying Monoclonal Antibodies (mAb) and Antibody-Drug Conjugates (ADC) in Biological Samples. Current Pharmacology Reports, 2018, 4, 45-63.	1.5	21
12	Discovery of Peptidomimetic Antibody–Drug Conjugate Linkers with Enhanced Protease Specificity. Journal of Medicinal Chemistry, 2018, 61, 989-1000.	2.9	63
13	Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia. MAbs, 2018, 10, 1312-1321.	2.6	13
14	High-Resolution Accurate-Mass Mass Spectrometry Enabling In-Depth Characterization ofin VivoBiotransformations for Intact Antibody-Drug Conjugates. Analytical Chemistry, 2017, 89, 5476-5483.	3.2	42
15	Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein– and Peptide–Payload Conjugates: Application to THIOMAB Antibody–Drug Conjugates. Bioconjugate Chemistry, 2017, 28, 2086-2098.	1.8	43
16	Custom-Designed Affinity Capture LC-MS F(ab′)2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates. Analytical Chemistry, 2016, 88, 11340-11346.	3.2	53